Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
106.50    0.00 (0.00%)
Bid:
104.00
Ask:
109.00
Spread: 5.00 (4.808%)
Market Cap: £64.07m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

First CMS to support FIDO enterprise attestation

24 Jul 2025 07:00

RNS Number : 3147S
Intercede Group PLC
24 July 2025
 

RNS Reach

24 July 2025

INTERCEDE GROUP plc

('Intercede', the 'Company' or the 'Group')

Intercede MyID is the first CMS to support FIDO enterprise attestation.

MyID CMS and Yubico integration delivers complete solution for enterprise passkey management

Intercede, the leading cybersecurity software company specialising in digital identities, today announces that the latest version of its credential management system - MyID CMS - is the first to support Enterprise Attestation within the FIDO authentication framework. Integrated with Yubico's industry-first Enterprise Attestation-enabled security keys - the YubiKey, MyID CMS v12.15 delivers a complete solution for organisations requiring the highest levels of security and device control.

Enterprise Attestation represents a critical advancement in enterprise security architecture, providing organisations with the ability to identify and verify individual authenticators before allowing access to regulated and protected environments. Unlike standard FIDO implementations that prioritise user privacy through anonymous attestation, Enterprise Attestation enables IT administrators to maintain precise visibility and control over security devices deployed across their organisation.

Allen Storey, Chief Product Officer at Intercede said:

"Our customers are often used to the levels of control, management, tracking and traceability that PKI smart cards provide, where each device has a unique serial number that ensures they are only issuing keys that they own. Enterprise Attestation enables FIDO authenticators to be uniquely identified, bringing the increased security and visibility that our high-assurance customers require.

Organisations can now deploy passwordless authentication at scale while maintaining the device-level control that enterprise security policies demand. This combination of security and manageability removes the final barriers to widespread FIDO adoption in regulated environments."

The new capabilities within MyID CMS addresses a persistent challenge in enterprise FIDO deployments: the gap between strong authentication and organisational control. With Enterprise Attestation, only approved, company-issued authenticators are permitted to be issued to access sensitive systems, while maintaining detailed audit trails of device management across the organisation.

Key benefits of the integrated solution include:

· Device-level visibility: Complete tracking and management of security keys throughout their lifecycle

· Policy enforcement: Granular control over which devices can access specific resources

· Audit compliance: Comprehensive logging and reporting for regulatory requirements

· Risk mitigation: Immediate ability to identify and revoke compromised or lost devices

· Seamless integration: Native support within existing identity and access management infrastructure.

In addition to Enterprise attestation, MyID CMS v12.15 adds support for PIN management features including minimum PIN length and forcing a PIN change at first usage. These enable 'issue on behalf of' scenarios and bring additional organisational control and security benefits.

Intercede's collaboration with Yubico gives organisations access to the complete technology stack needed for the deployment of YubiKeys at scale. YubiKey's are the first hardware authenticators to implement Enterprise Attestation capabilities, providing the foundation for the MyID CMS platform.

Jeff Wallace, SVP of Product at Yubico said:

"Enterprise Attestation is a critical capability for organisations that require precise control over their security infrastructure, enabling them to more easily track and allow only trusted and approved devices that are designed and configured specifically for the customers unique needs.

Our partnership with Intercede provides enterprises with a complete ecosystem for deploying FIDO authentication, while preserving the device-level visibility and management required in regulated environments."

Enterprise Attestation functionality is particularly valuable for organisations with strong security requirements, including government agencies, financial services, healthcare, and critical infrastructure providers. These sectors often require detailed device tracking and the ability to restrict access to only pre-approved authenticators.

Demonstration and Implementation

Intercede and Yubico will be providing in-depth education sessions on Enterprise Attestation implementation at the upcoming Authenticate conference on the 13th to 15th October 2025. Organisations can also watch a series of online demonstrations that showcase how MyID CMS addresses real-world scenarios, including device enrolment, policy management, and audit reporting functions.

To watch the videos, visit: www.intercede.com

Availability

MyID CMS 12.15 is available immediately for new and existing Intercede customers.

For more information about Intercede's Enterprise Attestation solution and to schedule a one-to-one demonstration, visit www.intercede.com

ENQUIRIES

Intercede Group plc

Tel. + 44 (0)1455 558111

Klaas van der Leest

CEO

Nitil Patel

CFO

 

 

Cavendish Capital Markets Limited

Tel. + 44 (0)20 7220 0500

Marc Milmo/ Fergus Sullivan

Corporate Finance

Tim Redfern/ Jamie Anderson

ECM

 

 

About Intercede

Intercede is a cybersecurity software company specialising in digital identities and strong authentication, and its innovative solutions enable organisations to protect themselves against the number one cause of data breach: compromised user credentials.

The Intercede suite of products allows customers to choose the level of security that best fits their needs, from Secure Registration and ID Verification to Password Security Management, One-Time Passwords, FIDO and PKI. Uniquely, Intercede provides the entire set of authentication options from Passwords to PKI, supporting customers on their journey to passwordless and stronger authentication environments. In addition to developing and supporting Intercede software, the Group offers professional services and development capabilities as well as managing the world's largest password breach database.

For over 20 years, global customers in government, aerospace and defence, financial services, healthcare, telecommunications, cloud services and information technology have trusted Intercede solutions and expertise in protecting their mission critical data and systems at the highest level of assurance.

For more information visit: www.intercede.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGZGZNNFVGKZM
Date   Source Headline
23rd Jun 20267:00 amRNSFinal Results
15th Jun 20267:00 amRNS-RExtension of Partnership with Swissbit
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.